Orserdu Approved for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

The FDA has approved Orserdu for postmenopausal women or adult men with estrogen receptor (ER)-positive, ...

FEBRUARY 5, 2023